Nucleotide Market

How big is Nucleotide Market in 2026?

Market value rises from USD 718.3 million in 2025 to USD 759.3 million in 2026 and is projected to reach USD 1,323.0 million by 2036.

Nucleotide materials are increasingly used in pharmaceutical and research activities. This includes DNA synthesis and assay development, where the same material is used in repeated analytical and manufacturing processes. As these processes move ahead, the quality of the nucleotide material becomes more important. Any variation can affect amplification or synthesis after the process has been qualified. The buyer then needs to review the process before using the material again. This is why purity and batch control remain important. Traceability and change management are also required as programs move from research work to controlled production during 2026 to 2036.

Country demand is expected to follow the pace of research activity and biopharma manufacturing in each market. South Korea is expanding biopharma production and genomic research. This is giving the country a stronger base for regulated nucleotide use. Japan is supporting genomic drug discovery, while the UK is developing research and manufacturing under its life-sciences plan. Germany is building genomic infrastructure. The USA is also linking sequence data with clinical research. These developments are expected to support precision medicine genomics and nucleotide demand through 2036. Buyers will still check documentation and process fit before changing a material. Technical support and supply continuity are also expected to influence the final purchase.

Key Takeaways of Nucleotide Market

• Pharmaceutical and research workflows will continue to require qualified nucleotide materials because purity or lot changes can disrupt validated processes through 2036.
• Pharmaceuticals are estimated to hold 63.4% of application demand in 2026, with strict specification and replacement requirements supporting this position.
• TaqMan allelic discrimination is estimated to hold 47.5% of technology demand in 2026, with standardized probe-based genotyping supporting this position.
• Nucleotide Type separates canonical purine and pyrimidine products from modified or other nucleotide products used across research and formulation workflows.
• Supplier changes will continue to require requalification when replacement materials alter assay performance, formulation behavior, process control, or regulatory documentation.
• Current evidence supports active nucleotide-related roles for KYOWA HAKKO BIO CO., LTD., Ajinomoto Co., Inc., and Angel Yeast Co.

Analyst Perspective

“Regulated nucleotide demand will continue to favor suppliers that carry specification control from development into routine production. Qualification is becoming more difficult when material changes affect validated assays, manufacturing steps, or regulatory documentation.”

- Nandini Roy Choudhury, Principal Consultant, Future Market Insights.

How is the Nucleotide Market segmented?

The Nucleotide Market is segmented by Application, Technology, Nucleotide Type, and Region.

The FMI report analyzes three primary segmentation categories covering application, technology, and nucleotide type. Region is shown separately, while the country comparison covers five countries.

Application category includes pharmaceuticals, diagnostics research, food & beverage additive, animal feed additive, and others.

Technology covers TaqMan allelic discrimination, SNP by pyrosequencing, gene chips & microarrays, and others.

Nucleotide type separates canonical purine nucleotides, canonical pyrimidine nucleotides, and modified or other nucleotide products.

What makes pharmaceuticals central to the Application category?

Pharmaceuticals are expected to account for 63.4% of application demand in 2026, supported by strict qualification and replacement requirements.

Pharmaceuticals are expected to remain the leading application in the nucleotide market through 2036. Nucleotide materials are used at the stage of active ingredients and intermediates. They are also needed during analytical method work and process development. Before a material is used regularly, buyers check its identity and purity. They then review the impurity profile along with traceability and change control records. The same requirement is found in clinical diagnostics where laboratories need repeatable molecular reagents. Finished therapies are outside the scope of this market. Upstream materials used in active ingredient synthesis, analytical method development, and process qualification remain in scope. Any change to these materials can trigger analytical checks, process review, and additional documentation before purchasing resumes.

• Pharmaceuticals are estimated to hold 63.4% of application demand in 2026, supported by strict qualification and replacement costs.
• Qualified pharmaceutical supply is expected to favor materials with consistent identity, purity, traceability, and change-control documentation through 2036.

Why does TaqMan allelic discrimination lead the Technology category?

TaqMan allelic discrimination is estimated to represent 47.5% of technology demand in 2026, reflecting standardized probe-based genotyping workflows.

TaqMan allelic discrimination is expected to remain a leading technology through 2036. The method uses sequence-specific primers with two fluorescent probes for genotype calls during real-time PCR. A laboratory can use the method with qPCR instruments and established master mixes. Plate formats and analysis software support the same workflow. Thermo Fisher offers over 17 million predesigned SNP assays along with custom formats. This gives laboratories a familiar route for targeted genotyping and reduces early method-development work. A supplier change can still affect amplification or signal separation. The laboratory may need to check the assay data before the method is used routinely again.

• TaqMan allelic discrimination is estimated to hold 47.5% of technology demand in 2026, supported by standardized probe-based workflows.
• Fixed primers and allele-specific probes are expected to keep reagent compatibility important because material changes can require performance verification before routine testing.

What are the drivers, restraints and opportunities in the Nucleotide Market?

Through 2036, regulated nucleic-acid adoption is expected to remain the key driver. Qualification and batch-control burden will remain the key restraint. Application-specific fermentation-derived supply is expected to provide the key opportunity.

• Driver: Regulated nucleic-acid development will continue to increase demand for nucleotide materials that retain controlled specifications through 2036.
• Restraint: Qualification and batch-control requirements will continue to limit supplier changes after reagents or ingredients enter validated processes.
• Opportunity: Application-specific fermentation-derived nucleotide supply is expected to expand across food, feed, and bioprocess uses through 2036.

Regulated nucleic-acid adoption

Use of regulated nucleic-acid therapies is increasing the need for controlled nucleotide materials. Regulatory approvals for nucleic-acid therapies continue to expand. These programs require controlled nucleotide materials during upstream chemistry, analytical method development, and process qualification. As such programs move from research to licensed production, the need for traceable, specification-controlled nucleotide inputs is expected to increase through 2036.  Molecular diagnostics are also using nucleotide materials in amplification and genotyping activities. This is creating regular demand from laboratories that run repeatable molecular workflows. Suppliers are expected to benefit when purity and lot consistency remain stable. Documentation and supply are also required as a program moves from research to qualified production.

Qualification and batch-control burden

Supplier change becomes difficult after a material enters a qualified process. The buyer first needs to show that the replacement material will maintain the validated process. It must also support the finished-product control strategy. FDA draft guidance issued in January 2025 discusses batch uniformity and drug-product integrity under 21 CFR 211.110. The same concern is seen in point-of-care molecular diagnostics where reagent performance needs to remain repeatable. Buyers review certificates and impurity limits before making a change. Storage conditions and change notices are also checked. Past lot behaviour can further affect the decision. A material may appear similar, but the qualification process can still delay the purchase.

Application-specific fermentation-derived supply

Fermentation-derived nucleotides are used in food and feed applications. They are also used in industrial bioprocessing. These uses follow a different qualification route from pharmaceutical applications. Angel Yeast's 2025 catalogue lists YeaNucleo yeast nucleotide products for feed and nutrition use. Buyers of animal feed additives first check dosage and stability. Sensory effect and permitted use are then reviewed for the target formulation. The product also needs to work with the premix method used by the buyer. This is why application support remains important. The trend is expected to support demand for application-specific grades through 2036.

Which country CAGRs are covered in the Nucleotide Market?

Country	CAGR
South Korea	7.6%
Japan	6.8%
UK	6.0%
USA	5.6%
Germany	5.3%

How do country-level CAGRs compare in the Nucleotide Market?

The country comparison covers five markets for the 2026 to 2036 forecast period. South Korea and Japan are included in the comparison. The UK is also covered. The USA and Germany are also part of the comparison. The country CAGRs are projected to range from 5.3% to 7.6%. These rates show the expected growth pace and do not show absolute nucleotide revenue. Research funding differs in these countries. Pharmaceutical production also follows a different path in each market. Clinical genomics and supplier qualification further influence the outlook. These factors are expected to shape nucleotide demand through 2036.

• South Korea is expanding export-oriented biohealth manufacturing, and public support is expected to reinforce pharmaceutical and biotechnology scale through 2036.
• Japan is advancing genomic drug discovery, and national programs are expected to sustain demand for sequence-linked therapeutic development through 2036.
• The UK is linking life-sciences research with advanced manufacturing, which is expected to support regulated health innovation through 2036.
• The USA is expanding genomic research infrastructure, while distinct qualification requirements are expected to continue across pharmaceutical, diagnostic, food, and feed uses.
• Germany is building governed genomic medicine infrastructure, and laboratory standards are expected to keep shaping procurement through 2036.

Order patterns are expected to differ by country. Research capacity and approved applications are different in each market. Supplier qualification routes also affect how buyers place their orders.

Country-wise Analysis

• South Korea is expected to grow at 7.6% CAGR from 2026 to 2036. The country is expanding biohealth manufacturing along with genomic research. This is increasing the need for regulated inputs across the wider biohealth sector. In March 2026, the Ministry of Health and Welfare reported USD 27.9 billion in 2025 biohealth exports. Pharmaceutical exports reached USD 10.4 billion for the first time. These figures show the size of the wider biohealth base. They do not show nucleotide revenue. Domestic whole genome sequencing programs are also expanding. As these activities grow, suppliers will need to provide local technical support and clear documentation. Qualification can delay a material change after it enters production. This is expected to keep supply continuity important through 2036.
• Japan is projected to grow at 6.8% CAGR from 2026 to 2036. The country is supporting genomic drug discovery and laboratories are following strict traceability requirements. In March 2025, AMED opened a call under its genomic drug-discovery platform program. The program supports whole-genome data and domestic information infrastructure for personalized medicine and drug discovery. Such work is expected to increase the use of controlled nucleotide reagents in sequencing and amplification. Assay development is also likely to support demand. A method change can require verification before a laboratory accepts replacement material. Technical support is therefore expected to remain important in the country.
• The UK is projected to grow at 6.0% CAGR from 2026 to 2036. The country is expanding life-sciences research and advanced manufacturing. The government published its Life Sciences Sector Plan in July 2025. Progress under the plan was updated in July 2026. The plan connects research and investment with manufacturing and health innovation across the country. Nucleotide suppliers are serving discovery laboratories and biopharma development. They also support molecular testing where material quality is linked with validated methods. Before a material is transferred into production, buyers are expected to check documentation and lead time. Change control and supply support are expected to remain important during the transfer.
• The USA is projected to grow at 5.6% CAGR from 2026 to 2036. The country has a large genomic research base. In June 2026 NIH reported over 535,000 whole genome sequences in the All of Us data release. This is expected to increase the recurring need for sequencing and molecular-analysis inputs. Nucleotide suppliers also serve pharmaceutical and diagnostic applications. Food and feed applications are served through a separate purchasing route. Food formulators use nucleotide salts as flavor enhancers. Research buyers focus on purity and nuclease control. Food buyers focus on permitted use and sensory performance. Suppliers are likely to match technical support with the needs of each application.
• Germany is projected to grow at 5.3% CAGR from 2026 to 2036. The country is building genomic medicine infrastructure. Laboratories are also strengthening records around research and clinical activities. The Federal Ministry of Health updated its genomDE information in March 2026. The program connects German genomic infrastructure with European data initiatives. It also supports secure secondary use of health information. Laboratories need controlled reagents and traceable purchasing records before routine use. Data governance does not directly set nucleotide volume. It is still increasing the documentation needed around connected workflows. Suppliers with material records and change support are expected to be better placed through 2036.

Who are the notable companies in the Nucleotide Market?

Notable current companies in the Nucleotide Market include KYOWA HAKKO BIO CO., LTD., Ajinomoto Co., Inc., and Angel Yeast Co. Public corporate information does not establish current nucleotide operations for Yeast Products Inc.

The report covers KYOWA HAKKO BIO CO., LTD. It also covers Ajinomoto Co., Inc. and Angel Yeast Co. The companies are working through different routes in the nucleotide market. KYOWA HAKKO BIO focuses on fermentation and pharmaceutical raw materials. Ajinomoto supplies nucleotide seasoning products. It also offers oligonucleotide development and manufacturing services. Angel Yeast supplies yeast-derived nucleotide products for nutrition and biotechnology uses. These activities are linked with the wider fermented ingredients supply chain. Buyers will compare specifications and quality records before selecting a supplier. They will also assess scale support and change control. Current corporate information does not establish an active nucleotide role for Yeast Products Inc. The company therefore remains a historical participant.

• Pharmaceutical and nucleic-acid specialists: KYOWA HAKKO BIO CO., LTD. and Ajinomoto Co., Inc. document regulated material or oligonucleotide capabilities.
• Yeast-derived nucleotide platform: Angel Yeast Co. documents yeast nucleotides and fermentation-nutrient products for nutrition and biotechnology applications.
• Historical participant: Yeast Products Inc. has past market references, while current public corporate information does not establish active nucleotide operations.

Competitive Benchmarking: Nucleotide Market

Company	Pharmaceutical & Nucleic-Acid Inputs	Food & Nutrition Nucleotide Ingredients	Oligonucleotide & Advanced Synthesis	Geographic Reach
KYOWA HAKKO BIO CO., LTD.	High	Medium	Medium	Japan; North America; Europe; Asia-Pacific
Ajinomoto Co., Inc.	High	High	High	Japan; Asia-Pacific; Americas; Europe; global CDMO markets
Angel Yeast Co.	Medium	High	Low	China with international markets across Asia-Pacific, Europe, and other regions
Yeast Products Inc.	Low	Low	Low	Current reach not verified

High ratings show broad documented capability across the scored fields. Medium ratings show a narrower role supported by direct evidence. Low ratings show limited public evidence. Geographic reach is descriptive and does not affect the capability rating.

Key Developments in the Nucleotide Market

• In April 2026, Angel Yeast showcased yeast-based bio-feed solutions at VIV Select India 2026 in New Delhi, presenting GroPro, which provides nucleic acids, functional peptides, and beta-glucans to support intestinal development and immunity in young animals.
• In October 2025, Ajinomoto Bio-Pharma Services and Gene Tools announced a collaboration linking early PMO research production with GLP and GMP manufacturing.
• In May 2025, Ajinomoto Co., Inc. and RIBOMIC reported extended pharmacokinetics for a nucleic-acid aptamer conjugate using AJICAP technology.

Key Players in the Nucleotide Market

Pharmaceutical and Nucleic-Acid Specialists

• KYOWA HAKKO BIO CO., LTD.
• Ajinomoto Co., Inc.

Yeast-Derived Nucleotide Ingredients

• Angel Yeast Co.

Historical Participant

• Yeast Products Inc.

Nucleotide Market - Report Scope

Coverage field	Report scope
Market breakdown	Application; Technology; Nucleotide Type
Quantitative Units	USD Million
Market Definition	Revenue covers discrete nucleotide and nucleotide-derived ingredient or reagent products sold within the Application, Technology, and Nucleotide Type segmentation. Included uses span Pharmaceuticals, Diagnostics Research, Food & Beverage Additive, Others, and Animal Feed Additive. Finished drugs, diagnostic instruments, complete testing systems, downstream finished foods or feeds, and adjacent or substitute ingredients are excluded. Bundled-system and service revenue is excluded unless the nucleotide reagent component is separately sold within scope.
Regions Covered	North America; Latin America; Western Europe; Eastern Europe; East Asia; South Asia and Pacific; Middle East and Africa
Countries Covered	Japan, USA, South Korea, UK, Germany
Key Companies	KYOWA HAKKO BIO CO., LTD.; Ajinomoto Co., Inc.; Angel Yeast Co.; Yeast Products Inc.
Forecast Period	2026 to 2036
Approach	Primary and secondary research with market triangulation.

Nucleotide Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments and findings from primary interviews. Validation also tested whether products, services, applications and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Nucleotide Market by Segments

Nucleotide Market segmented by Application:

• Pharmaceuticals
• Diagnostics Research
• Food & Beverage Additive
• Others
• Animal Feed Additive

Nucleotide Market segmented by Technology:

• TaqMan allelic discrimination
• SNP by pyrosequencing
• Gene chips & microarrays
• Others

Nucleotide Market segmented by Nucleotide Type:

• Canonical purine nucleotides
• Canonical pyrimidine nucleotides
• Modified and other nucleotide products

Nucleotide Market by Region

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Benelux
  • Nordics
• Eastern Europe
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• Source country: United States
  https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-dawnzera
  U.S. Food and Drug Administration. (2025, August 21). Drug Trials Snapshots: DAWNZERA.
• Source country: South Korea
  https://mohw.go.kr/gallery.es?act=view&b_list=12&bid=0003&cg_code=&keyField=&list_no=379895&mid=a10605040000&nPage=12&orderby=&vlist_no_npage=29
  Republic of Korea Ministry of Health and Welfare. (2026, March 3). 2025 biohealth industry exports reached a record USD 27.9 billion.
• Source country: United Kingdom
  https://www.gov.uk/government/publications/life-sciences-sector-plan
  UK Government. (2025, July 16). Life Sciences Sector Plan. Updated July 9, 2026.
• U.S. Food and Drug Administration. (2025, January). Considerations for Complying with 21 CFR 211.110. Draft Level 1 Guidance.
• National Institutes of Health. (2026, June 30). NIH’s All of Us Research Program is now the largest integrated genomics and health database in the world.
• Japan Agency for Medical Research and Development. (2025, March 17). FY2025 call for the genomic drug-discovery platform research program.
• German Federal Ministry of Health. (2026, March 2). Die deutsche Genom-Initiative - genomDE.
• Thermo Fisher Scientific. (n.d.). TaqMan SNP Genotyping Assays.
• Thermo Fisher Scientific. (n.d.). dNTP Mix (10 mM each).
• Ajinomoto Bio-Pharma Services. (2025, October 21). Ajinomoto Bio-Pharma Services and Gene Tools announce collaboration to expand access to PMO therapeutics.
• Ajinomoto Bio-Pharma Services. (2025, May 6). Successful extension of nucleic acid aptamer pharmacokinetics in joint research by Ajinomoto Co., Inc. and RIBOMIC Inc.
• Angel Yeast Co. (2025). Animal Nutrition product catalog: YeaNucleo yeast nucleotide.
• Angel Yeast Co. (2026, April 22). Angel Yeast highlights yeast-based bio-feed advantages at VIV Select India 2026.
• Angel Yeast Co. (2026, July). Angel Yeast showcases yeast-powered ingredient solutions at IFT FIRST 2026 in Chicago.
• Angel Yeast Co. (2025, July 17). Angel Yeast highlights pioneering yeast protein and sustainable solutions at IFT FIRST 2025, redefining the future of food.
• KYOWA HAKKO BIO CO., LTD. (2025, January 16). Notification: KYOWA HAKKO BIO Co., Ltd. received Close-Out Letter related to Warning Letter from the FDA.
• KYOWA HAKKO BIO CO., LTD. (2026, March). Message from President Hiroshi Nagano.
• Ajinomoto Co., Inc. (2025, October 31). Ajinomoto Co., Inc. enters licensing agreement with Astellas Pharma Inc. for biopharmaceutical development and manufacturing technology.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

This Report Answers

• How large is the Nucleotide Market in 2025, 2026, and 2036?
• What CAGR is projected for the Nucleotide Market from 2026 to 2036?
• Which Application segment holds the leading 2026 share?
• Which Technology segment holds the leading 2026 share?
• How is the Nucleotide Market segmented by Application, Technology, Nucleotide Type, and Region?
• How do forecast growth rates differ across South Korea, Japan, the UK, the USA, and Germany?
• Which current companies document relevant nucleotide ingredients or nucleic-acid manufacturing capability?
• What limits supplier switching after a nucleotide material enters a qualified or validated process?